Mediators of Inflammation / 2014 / Article / Tab 3 / Clinical Study
Urinary Eicosanoid Metabolites in HIV-Infected Women with Central Obesity Switching to Raltegravir: An Analysis from the Women, Integrase, and Fat Accumulation Trial Table 3 Multivariate generalized linear models of predictors of 24-week eicosanoid changes.
Covariate F2 -IsoP PGE-M PGI-M TxB2
(95% CI)
(95% CI)
(95% CI)
(95% CI)
Study arm (RAL versus PI/NNRTI) 0.25 (−0.79, 1.30) 0.63 1.6 (−4.5, 7.7) 0.60 0.04 (−0.02, 0.09) 0.19 0.12 (−0.02, 0.26) 0.10 PI use at baseline (yes versus no) 0.46 (−0.54, 1.46) 0.35 −3.9 (−9.6, 1.8) 0.17 0.004 (−0.05, 0.05) 0.85 0.06 (−0.07, 0.20) 0.35 Age ≥ 50 years (versus <50) 0.73 (−0.66, 2.12) 0.29 8.3 (0.3, 16.3) 0.04 0.02 (−0.06, 0.10) 0.59 −0.02 (−0.21, 0.17) 0.81 Current smoking (yes versus no) −0.37 (−1.54, 0.81) 0.53 0.9 (−6.0, 7.9) 0.78 −0.01 (−0.07, 0.05) 0.69 0.11 (−0.05, 0.27) 0.18 Baseline BMI 0.02 (−0.06, 0.09) 0.63 0.3 (−0.1, 0.7) 0.13 0.0005 (−0.003, 0.004) 0.80 0.007 (−0.003, 0.02) 0.16
BMI = body mass index; F2 -IsoP = F2 -isoprostanes; NNRTI = non-nucleoside reverse transcriptase inhibitor; PI = protease inhibitor; PGE-M = prostaglandin E2 metabolite; PGI-M = prostacyclin metabolite; RAL = raltegravir; TxB2 = thromboxane B2 .